Last reviewed · How we verify
Morphine Titration
Morphine is an opioid agonist that binds to mu opioid receptors in the central and peripheral nervous system to produce analgesia and other opioid effects.
Morphine is an opioid agonist that binds to mu opioid receptors in the central and peripheral nervous system to produce analgesia and other opioid effects. Used for Moderate to severe pain management, Cancer pain, Acute postoperative pain.
At a glance
| Generic name | Morphine Titration |
|---|---|
| Also known as | Morphine |
| Sponsor | University of Monastir |
| Drug class | Opioid agonist |
| Target | Mu opioid receptor (OPRM1) |
| Modality | Small molecule |
| Therapeutic area | Pain Management |
| Phase | Phase 3 |
Mechanism of action
Morphine works by activating mu opioid receptors, which are G-protein coupled receptors found throughout the brain, spinal cord, and peripheral tissues. This activation modulates pain perception, reduces anxiety, and produces sedation. The drug is commonly used in titration protocols where doses are gradually increased to achieve optimal pain control while minimizing adverse effects.
Approved indications
- Moderate to severe pain management
- Cancer pain
- Acute postoperative pain
Common side effects
- Constipation
- Nausea
- Drowsiness
- Dizziness
- Respiratory depression
- Pruritus
Key clinical trials
- Opioid Free and Opioid Based Anesthesia in Elective Lumbar Spine Surgery
- Efficacy and Safety of Ofatumumab and Siponimod Compared to Fingolimod in Pediatric Patients With Multiple Sclerosis (PHASE3)
- Inhaled vs IV Opioid Dosing for the Initial Treatment of Severe Acute Pain in the Emergency Department (PHASE3)
- Magnetic Seizure Therapy in Bipolar Depression (MST-BpD) and Treatment Resistant Depression (MST-TRD) (NA)
- Magnetic Seizure Therapy for Psychotic Disorders (NA)
- Fentanyl Versus Hydromorphone in Patients on Mechanical Ventilation (PHASE2)
- IV PCA With or Without Continuous Dose vs Oral Opioid to Maintain Analgesia for Severe Cancer Pain After Successful Titration (PHASE3)
- Dexmedetomidine Versus Morphine During Cooling Therapy in Neonates (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Morphine Titration CI brief — competitive landscape report
- Morphine Titration updates RSS · CI watch RSS
- University of Monastir portfolio CI